ClinicalTrials.gg
WithdrawnNCT02226133VALETUpdated May 5, 2015

Video-Assisted Left Atrial Appendage Exclusion Trial

An interventional study of LAAx, Inc. TigerPaw® System II in Heart Diseases, sponsored by LAAx, Inc.. Withdrawn at 4 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-05-05.

Sponsored by LAAx, Inc. · Not applicable, Interventional, and Prevention

Why this study was withdrawn
stopped for operational reasons
Phase
Not applicable
Study type
Interventional
Enrollment
0
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

Exclusion of the LAA(Left Atrial Appendage) using the TigerPaw II System with VATS technique is safe and effective.

Read the detailed description

The objective of this confirmatory study is to demonstrate that the LAAx, Inc. TigerPaw® II System can be safely and effectively used to exclude the Left Atrial Appendage (LAA) during cardiac surgery utilizing thoracoscopic camera and light source and thus remove, from the cleared indication for use, the direct vision limitation.

02

Conditions studied

  • Heart Diseases

Browse trials for

03

In context

Heart Diseases

3,673 studies on the registry are indexed under Heart Diseases; 458 are open to participants now.

Browse Heart Diseases studies →

Lead sponsor

LAAx, Inc. is the lead sponsor of 2 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Greater than or equal to 18 years of age;
  2. Capable and willing to give informed consent;
  3. Able and willing to complete a 30 day ± 7 day follow-up evaluation;
  4. Ejection fraction ≥ 30%;
  5. Life expectancy of > 1 year;
  6. Stroke Risk (CHADS score of ≥ 1), CHADS scoring: CHF=1 point, Hypertension (or treated hypertension) = 1 point, Age > 75 = 1 point, Diabetes = 1 point, Prior stroke or TIA = 2 points;
  7. Subjects suitable for elective Video-Assisted Thoracoscopic Surgical (VATS) procedure(s) including, but not limited to, cardiac surgery for one or more of the following:

    1. mitral valve repair or replacement,
    2. aortic valve repair or replacement,
    3. tricuspid valve repair or replacement,
    4. coronary artery bypass procedures,
    5. concomitant surgical (ablation or cut and sew) Maze procedure and other ablation procedures
    6. hybrid procedures including combination surgical and interventional procedures and surgical procedures with a combination of left and right thoracic access sites

Exclusion criteria

Exclusion Criteria:

  1. Previous cardiac surgery;
  2. Active systemic or cutaneous infection or inflammation;
  3. Pre-existing immunodeficiency disorder and/or chronic use of systemic steroids not including intermittent use of inhaled steroids for respiratory diseases;
  4. Known, significant history of bleeding diathesis, coagulopathy, von Willebrand's disease or current platelet count \< 100,000 cells/mm3, baseline INR ≥1.8, or fibrinogen level less than 150 mg/dl (if received a fibrinolytic agent within prior 24 hours);
  5. Severe co-existing morbidities having a life expectancy of less than 1 year;
  6. Currently involved in any other investigational clinical trials that have not completed their primary endpoint or that may interfere with the TigerPaw study results;
  7. Thrombus in the LAA/LA;
  8. NYHA Class IV heart failure symptoms;
  9. Mental impairment or other conditions which may not allow the subject to understand the nature, significance and scope of the study and to cooperate with follow-up requirements;
  10. Preoperative need for an intra-aortic balloon pump;
  11. Significant anemia with a hemoglobin level less than 10 g/dL or a hematocrit less than 30%;
  12. Females who are pregnant, planning to become pregnant within 1 month of the procedure, or lactating;
  13. Extreme morbid obesity (BMI greater than 45 kg/m2);
  14. Any active medical condition that would preclude the patient from completing the study or would result in an unreasonable risk;
  15. Contraindication to Transesophageal Echocardiography (TEE);
  16. Need for emergent cardiac surgery (e.g., cardiogenic shock);
  17. Creatinine >200 umol/L;
  18. Renal failure requiring dialysis or hepatic failure;
  19. A known drug and/or alcohol addiction;
  20. Concurrent chemotherapy.
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Exclusion of Left Atrial Appendage

    Left Atrial Appendage (LAA) occlusion, using the LAAx, Inc. TigerPaw® System II (delivery system and implant/Fastener) using VATS techniques,

    Device: LAAx, Inc. TigerPaw® System II

Interventions

  • DeviceLAAx, Inc. TigerPaw® System II

    Exclusion of Left Atrial Appendage.

    Also known as: LAAx,Inc. TigerPaw System

06

What researchers measure

Primary outcomes

  1. rate of device related adverse and serious adverse events

    Time frame: 30 (plus or minus 7) days

Secondary outcomes

  1. Exclusion of the Left Atrial Appendage

    Primary effectiveness will be measured by the percentage of patients with exclusion of the LAA assessed intraoperatively via endoscopic image and transesophageal echocardiography (TEE).

    Time frame: 30 days

07

Study locations

4 sites
  • ValleyCare Health System-Pleasanton
    Pleasanton, California 94588, United States
  • UMD School of Medicine
    Baltimore, Maryland 21201, United States
  • Geisinger Heart Institute
    Danville, Pennsylvania 18711, United States
  • Lankenau MOB East
    Wynnewood, Pennsylvania 19096, United States
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 5, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02226133
Lead sponsor
LAAx, Inc.
Responsible party
Sponsor
First posted
Aug 27, 2014
Start date
Apr 2015
Primary completion
Sep 2015 (estimated)
Completion
Dec 2015 (estimated)
Last update
May 5, 2015

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in May 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion